Skip to content

GeneFrontier ジーンフロンティア株式会社

  • Solutions
    • Koutai Shokunin
      • Overview
      • Price
      • Flow
      • Cases
      • Publications
      • FAQ
    • PUREfrex®
      • Overview
      • Lineup
      • Technology
    • PUREfrex® RD
      • Overview
      • Cases
      • Publications
      • FAQ
    • Drug Discovery
      • Overview
  • Support
    • Downloads
      • Koutai Shokunin
      • PUREfrex®
      • PUREfrex® RD
    • Cases
      • Koutai Shokunin
      • PUREfrex®
      • PUREfrex® RD
    • News
      • Exhibition
      • Campaign
      • Others
    • FAQ
      • Koutai Shokunin
      • Purefrex®
      • PUREfrex® RD
  • Company
    • Intoroduction
    • Corporate Profile
    • Access
    • Partners
  • Contact
    • General Contact Form
    • Koutai Shokunin Contact Form
    • PUREfrex® Contact Form
検索 検索
日本語
English
ジーンフロンティア株式会社

GeneFrontier

Innovative Solution Provider in Protein Engineering and Biologics

ジーンフロンティア株式会社

HuCAL® Custom Monoclonal Antibody Generation

ジーンフロンティア株式会社

Reconstituted cell-free protein synthesis kit

Solutions

  • PUREfrex®

  • Koutai Shokunin

  • PUREfrex® RD

  • Drug Discovery

PUREfrex®

  • TOP
  • Overview
  • Lineup
  • Technology
  • Download
  • Cases
  • Publications
  • FAQ
  • Contact
Detail

Koutai Shokunin

  • TOP
  • Price
  • Flow
  • Download
  • Cases
  • Publications
  • FAQ
  • Contact
Detail

PUREfrex® RD

  • TOP
  • Download
  • Cases
  • Publications
  • FAQ
  • Contact
Detail

Drug Discovery

  • Overview
  • Contact
Detail

News

  • Troubleshooting PDF Display Issues in Microsoft Edge

    Others
    2024.11.28
  • System maintenance

    Others
    2024.07.11
  • GeneFrontier Co-Hosted Morning Seminar at the 21st IUPAB Congress 2024

    Exhibition PUREfrex®
    2024.06.13
  • Publication on N-terminal amino acid affects the translation efficiency at lower temperatures in the PUREfrex® has been released.

    Others PUREfrex®
    2024.05.23
  • Presentation: PEGS Boston 2024

    Exhibition PUREfrex®
    2024.05.07
More

Cases

  • PUREfrex® RD

    New Biologics projects

    2023.01.04
  • PUREfrex® RD

    Small Molecule projects

    2023.01.04
  • PUREfrex® RD

    Cyclic Peptide projects

    2021.05.10
  • PUREfrex®

    Influence of reducing reagents on the redox state

    2021.01.27
  • PUREfrex®

    Improvement of specific activity by methylation of release factors (RF1 and RF2)

    2021.01.26
More
  • Solutions
    • Koutai Shokunin
    • PUREfrex®
    • PUREfrex® RD
    • Drug Discovery
  • Support
    • Downloads
    • Cases
    • News
    • FAQ
  • Company
    • Intoroduction
    • Corporate Profile
    • Access
    • Partners
  • Contact
    • General Contact Form
    • Koutai Shokunin Contact Form
    • PUREfrex® Contact Form
  • Recruit
  • Privacy Policy
Copyright © 2025, GeneFrontier Corporation All rights reserved.